Lv61
2140 积分 2023-07-29 加入
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
16天前
已完结
Biological Agents in the Treatment of Crohn's Disease: A Propensity Score–Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study
16天前
已完结
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn’s Disease
16天前
已完结
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST
16天前
已完结
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
16天前
已完结
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
16天前
已完结
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and Adjusted Regimen in Real World
27天前
已关闭
Low muscle mass is associated with efficacy of biologics in Crohn’s disease
27天前
已完结
One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study
27天前
已完结
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients
27天前
已完结
皖公网安备34019202002308
